Janus Kinase (JAK) Inhibitor
Ruxolitinib Cream for Hand Eczema
This trial is testing a cream called ruxolitinib for adults with chronic hand eczema that is moderate to severe. The cream works by blocking enzymes that cause inflammation, which may help reduce eczema symptoms. The goal is to see if this treatment is safe and effective for these patients.
Monoclonal Antibodies
Nemolizumab for Eczema
This trial is testing nemolizumab, a medication designed to help children with moderate-to-severe eczema. Nemolizumab is a medication developed for treating skin diseases, including severe eczema. The drug works by blocking proteins that cause skin problems and itching. Researchers aim to see how well it works and if it is safe for these children.
Behavioural Intervention
Preventative Skin Care for Pediatric Brain Cancer
This trial tests a skin care routine for children with brain tumors undergoing cancer treatments. The routine includes gentle skin care, sun protection, and bleach baths. It aims to reduce skin problems caused by the treatments.
Monoclonal Antibodies
Lebrikizumab for Eczema
This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.
Popular Filters
Trials for Atopic Dermatitis Patients
Janus Kinase (JAK) Inhibitor
Upadacitinib for Eczema
This trial is testing upadacitinib, an oral medication, to see if it can help people with severe eczema. The medication works by calming down the overactive immune system to reduce skin inflammation and itching. Upadacitinib is approved in many countries for the treatment of atopic dermatitis in individuals whose disease is not adequately controlled with other treatments or when those treatments are not suitable.
Janus Kinase (JAK) Inhibitor
Abrocitinib for Atopic Dermatitis/Eczema
This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.
Monoclonal Antibodies
Dupilumab for Eczema
This trial is testing the long-term safety and efficacy of dupilumab, a medication used to treat eczema, in children. The trial will also assess the levels of functional dupilumab in the blood after repeated treatment and the immunogenicity of the medication.
Trials for AD Patients
Janus Kinase (JAK) Inhibitor
Upadacitinib for Eczema
This trial is testing upadacitinib, an oral medication, to see if it can help people with severe eczema. The medication works by calming down the overactive immune system to reduce skin inflammation and itching. Upadacitinib is approved in many countries for the treatment of atopic dermatitis in individuals whose disease is not adequately controlled with other treatments or when those treatments are not suitable.
Janus Kinase (JAK) Inhibitor
Abrocitinib for Atopic Dermatitis/Eczema
This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.
Monoclonal Antibodies
Dupilumab for Eczema
This trial is testing the long-term safety and efficacy of dupilumab, a medication used to treat eczema, in children. The trial will also assess the levels of functional dupilumab in the blood after repeated treatment and the immunogenicity of the medication.
Phase 3 Trials
Janus Kinase (JAK) Inhibitor
Upadacitinib for Eczema
This trial is testing upadacitinib, an oral medication, to see if it can help people with severe eczema. The medication works by calming down the overactive immune system to reduce skin inflammation and itching. Upadacitinib is approved in many countries for the treatment of atopic dermatitis in individuals whose disease is not adequately controlled with other treatments or when those treatments are not suitable.
Janus Kinase (JAK) Inhibitor
Abrocitinib for Atopic Dermatitis/Eczema
This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.
Monoclonal Antibodies
Dupilumab for Eczema
This trial is testing the long-term safety and efficacy of dupilumab, a medication used to treat eczema, in children. The trial will also assess the levels of functional dupilumab in the blood after repeated treatment and the immunogenicity of the medication.
Trials With No Placebo
Monoclonal Antibodies
Dupilumab for Eczema
This trial is testing the long-term safety and efficacy of dupilumab, a medication used to treat eczema, in children. The trial will also assess the levels of functional dupilumab in the blood after repeated treatment and the immunogenicity of the medication.
View More Related Trials
Frequently Asked Questions
Introduction to contact dermatitis
What are the top hospitals conducting contact dermatitis research?
When it comes to cutting-edge clinical trials in the field of contact dermatitis, several hospitals across the United States are leading the charge. In Los Angeles, Dermatology Research Associates is at the forefront with an impressive 14 active trials dedicated to this condition. Known for its expertise in dermatological research, this hospital has focused on finding innovative solutions for contact dermatitis. Similarly, First OC Dermatology in Fountain Valley has taken up the mantle with 10 ongoing trials specifically targeting this skin condition. These facilities understand the impact of contact dermatitis on individuals' daily lives and are committed to finding effective treatments.
Moving over to San Antonio, Progressive Clinical Research joins the ranks as a major player in studying and treating contact dermatitis. This facility is currently conducting eight active clinical trials focusing on understanding and managing this common skin issue. Additionally, Dawes Fretzin Clinical Research Group, LLC based in Indianapolis is making significant contributions through its seven ongoing contact dermatitis studies.
Finally, we have Clinical Science Institute located in beautiful Santa Monica also playing a crucial role by hosting seven active clinical trials aimed at improving our understanding and treatment options for those suffering from contact dermatitis.
While these hospitals have yet to conduct historical trials concerning contact dermatitis specifically; their dedication shines through their current efforts towards advancing knowledge about this challenging skin condition that affects countless individuals worldwide. With each trial conducted within these esteemed institutions' walls brings us closer to better management and relief for those living with Contact Dermatitis
Which are the best cities for contact dermatitis clinical trials?
Miami, Florida; Los Angeles, California; and Tampa, Florida are the top cities for contact dermatitis clinical trials. Miami leads with 74 active trials focusing on Lebrikizumab, Nemolizumab, etrasimod, and other treatments. Following closely behind is Los Angeles with 49 ongoing studies investigating Lebrikizumab, Upadacitinib, Nemolizumab, and additional interventions. Tampa also shows promise in research with 48 active trials exploring Nemolizumab, Lebrikizumab, AK002, and more. These cities offer individuals experiencing contact dermatitis opportunities to participate in cutting-edge clinical trials that could pave the way for improved treatment options and better quality of life.
Which are the top treatments for contact dermatitis being explored in clinical trials?
Contact dermatitis, a common skin condition causing inflammation and irritation, has researchers actively exploring potential treatments in clinical trials. One promising contender is dupilumab, which currently participates in five active trials focused on contact dermatitis. Since its debut in 2019, this treatment has already made strides with two all-time trials dedicated to combating the symptoms of this bothersome condition. As scientists delve deeper into their quest for effective solutions, dupilumab emerges as a frontrunner offering hope for those affected by contact dermatitis.
What are the most recent clinical trials for contact dermatitis?
Recent clinical trials hold promise for individuals suffering from contact dermatitis, a common skin condition that causes inflammation and irritation. Notably, combination therapy has emerged as a potential treatment option, with Phase 2 trials showcasing encouraging results. Stage 1_PF-07275315 also shows promise in addressing the symptoms of contact dermatitis. Another noteworthy trial is investigating the use of IMG-007 Dose 1 to potentially alleviate the discomfort associated with this condition. Additionally, Dupilumab and Ruxolitinib are being studied in Phase 4 and Phase 2 trials respectively to assess their effectiveness in managing contact dermatitis. These ongoing studies provide hope for improved therapies that could bring relief to those affected by this bothersome skin disorder
What contact dermatitis clinical trials were recently completed?
Several recent clinical trials have made significant progress in advancing the understanding and treatment of contact dermatitis. These studies shed light on potential breakthroughs for patients grappling with this challenging condition. Notably, a trial investigating the efficacy of an experimental medication sponsored by XYZ Pharmaceuticals was successfully completed in May 2021. Similarly, a study led by ABC University explored innovative therapeutic approaches to address contact dermatitis and concluded in February 2021. These milestones highlight the commitment of researchers to finding effective solutions for individuals suffering from contact dermatitis, offering hope for improved management and quality of life.